Skip to content

USCB Financial Holdings, Inc. USCB Loans collectively evaluated for impairment

Loans collectively evaluated for impairment at other companies

JPMorgan Chase logo
JPMorgan ChaseJPM
Citizens Financial Services, Inc. logo
Citizens Financial Services, Inc.CZFS
Hope Bancorp logo
Hope BancorpHOPE

Other financials

Income statement

See full
Revenue$26.2M+14.7%
Net income$9.4M+22.1%
EPS (diluted)$0.51+34.2%

Balance sheet

See full
Cash & equivalents$79.0M-19.4%
Total debt$4.8M-38.3%
Total equity$223.2M-0.8%
Total assets$2.8B+6.3%

Cash flow

See full
Operating cash flow$15.3M+4.4%
CapEx$320.0K+596%
Free cash flow$15.0M+2.6%

Valuation

See full
Market cap$363.27M+13.5%
Enterprise value$289.06M+25.8%
P/E13.1×+1.5×
P/S3.9×+0.2×

Profitability

See full
Net margin29.7%-1.8pp
FCF margin55.3%

Returns & leverage

See full
Return on equity12.4%-0.8pp
Debt / equity0.0×

Where this comes from

Reported directly by USCB Financial Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinancingReceivableCollectivelyEvaluatedForImpairment.

The official record: USCB Financial Holdings, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about USCB Financial Holdings, Inc.'s loans collectively evaluated for impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is USCB Financial Holdings, Inc.'s loans collectively evaluated for impairment?
USCB Financial Holdings, Inc. (USCB) reported loans collectively evaluated for impairment of $2.23B in Q1 2026.
How has USCB Financial Holdings, Inc.'s loans collectively evaluated for impairment changed year-over-year?
USCB Financial Holdings, Inc.'s loans collectively evaluated for impairment increased by 10.3% year-over-year, from $2.02B to $2.23B.
What is the long-term trend for USCB Financial Holdings, Inc.'s loans collectively evaluated for impairment?
Over 3 years (2022 to 2025), USCB Financial Holdings, Inc.'s loans collectively evaluated for impairment has grown at a 13.2% compound annual growth rate (CAGR), from $1.5B to $2.18B.